Non-Small Cell Lung Cancer
This study focused on determining the effectiveness of a short-term high-intensity interval training (HIIT) program to improve patients' cardiorespiratory fitness prior to NSCLC resection.
Atezolizumab (Tecentriq) is approved by the FDA for the treatment of metastatic NSCLC in specific cases or tumors with EGFR or ALK gene mutations.
The addition of pembrolizumab to carboplatin and pemetrexed improves overall response rate compared with chemotherapy alone and has a manageable safety profile in patients with newly diagnosed advanced nonsquamous NSCLC.
Treatment with the kinase inhibitor lenvatinib demonstrated promising activity in patients with RET-positive NSCLC.
IMRT was associated with lower rates of severe pneumonitis and cardiac doses compared with 3D-CRT in patients with locally advanced NSCLC.
Continued adoption of stereotactic body radiation therapy (SBRT) to treat early stage NSCLC improved OS and lung cancer-specific survival, according to a study presented at the 2016 annual meeting of the American Society for Radiation Oncology.
Adding WBRT to dexamethasone and best supportive care provides little additional benefit for patients with NSCLC and brain metastases who are ineligible to undergo resection or stereotactic radiotherapy.
Longer overall survival was achieved with TKIs targeting EGFR mutations in non-small cell lung cancer (NSCLC) patients.
Pneumonitis related to the use of PD-1 inhibitor therapy is higher among patients with NSCLC and RCC, and during combination therapy.
Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.
Patients receiving PD-1 or PD-L1 antibodies exhibited papular and nodular eruptions with scale, as well as mucosal lesions with lichenoid features, that were typically manageable with topical steroid treatment.
Results from phase II trial on the use of FDG-PET to evaluate the efficacy of an immunotherapy drug in the treatment of NSCLC.
Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.
In patients with completely resected stage IB NSCLC, adjuvant chemotherapy is associated with improved survival regardless of tumor size.
Biochemical Marker Is a Better Predictor of Adverse Effects in Patients with Non-small Cell Lung CancerJune 13, 2016
Albumin concentration with an established cutoff point is proven a better predictor of both chemotherapy toxicity and survival in patients with advanced lung cancer.
The largest database on outcomes with RET-directed therapy for RET-rearranged NSCLC to date confirms RET inhibitors are active in a proportion of patients, a study presented at the 2016 ASCO Annual Meeting has shown.
Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.
The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage EGFR-mutation-positive NSCLC.
Including Quality Measures In Treatment Regimens Increases Survival in Stage IIIA Non-Small Cell Lung CancerMay 26, 2016
When more quality measures are incorporated into patient care, survival rates for patients with stage IIIA non-small cell lung cancer (NSCLC) increase, but only 13% of eligible patients actually receive all 4 recommended quality measures.
Increased Risk of Noncancer Deaths Associated with Stereotactic Body Radiation Therapy for Lung CancerMay 16, 2016
High doses of SBRT, particularly to the left atrium of the heart and the superior vena cava, are associated with a small but increased risk of death from noncancer causes in patients with early stage NSCLC.
Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancerMay 05, 2016
[Cancer Management and Research] This research examines the use of proactive GI AE management strategies for patients with non-small-cell lung cancer being treated with ceritinib.
The most benefit from adding necitumumab to chemotherapy with gemcitabine and cisplatin occurred for patients whose advanced squamous NSCLC expressed EGFR.
Treatment benefit can be predicted through genotyping from blood plasma, according to several studies presented at ELCC 2016; however, plasma tests are unlikely to fully replace tissue biopsies.
Osimertinib effectively treats EGFR-mutated non-small cell lung cancer that has the T790M mutation, according to recent study findings.
Longer survival was achieved with stereotactic radiosurgery (SRS) alone than with whole-brain radiation therapy (WBRT) in patients with fewer than 4 brain metastases from NSCLC or breast cancer.
Continuation of ceritinib therapy beyond disease progression was associated with prolonged survival, according to results from a retrospective study of the use of ceritinib to treat advanced ALK-positive NSCLC.
In patients previously treated with crizotinib for ALK-positive NSCLC and brain metastases, ceritinib treatment elicited clinically meaningful whole-body and intracranial responses with an acceptable tolerability profile.
Significant sensitivity to cisplatin-based chemotherapy is signaled by the presence of low expression of SMARCA4/BRG1 in patients with earlier-stage NSCLC. Low expression of SMARCA4/BRG1 was also linked to a poor prognosis.
N3 nodal staging among patients with non-small cell lung cancer (NSCLC) was associated with a significantly higher risk for developing VTE.
Survival benefits were strongest for pemetrexed maintenance therapy followed by maintenance therapy with EGFR kinase inhibitors.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Prolactin Expression May Indicate Better Prognosis for Patients With TNBC
- Caregiver Mastery Linked to Patient Survival in Glioblastoma
- Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma
- Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|